NTRK2 and central nervous system cancer: Although entrectinib decreased the proliferation rate of xenografted NTRK2 wild-type DIPG cells in vivo, it did not further decrease the proliferation rate of NTRK2-KO glioma xenografts (Extended Data Fig. 2e,f), demonstrating that the mechanism of action of entrectinib in DIPG is mediated through TrkB.